Recent progress in adjuvant discovery for peptide-based subunit vaccines

References

• Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6:404 - 14; http://dx.doi.org/10.1038/nrd2224; PMID: 17473845
   PubMed Web of Science ®Google Scholar
• Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004; 5:460 - 4; http://dx.doi.org/10.1038/ni0504-460; PMID: 15116108
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Peptide-based subunit nanovaccines. Curr Drug Deliv 2011; 8:282 - 9; http://dx.doi.org/10.2174/156720111795256192; PMID: 21291373
   PubMed Web of Science ®Google Scholar
• Pruksakorn S, Currie B, Brandt E, Phornphutkul C, Hunsakunachai S, Manmontri A, Robinson JH, Kehoe MA, Galbraith A, Good MF. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994; 6:1235 - 44; http://dx.doi.org/10.1093/intimm/6.8.1235; PMID: 7981150
   PubMed Web of Science ®Google Scholar
• Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines 2010; 9:157 - 73; http://dx.doi.org/10.1586/erv.09.160; PMID: 20109027
   PubMed Web of Science ®Google Scholar
• Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 1995; 6:141 - 228; http://dx.doi.org/10.1007/978-1-4615-1823-5_7; PMID: 7551218
   PubMedGoogle Scholar
• Mata E, Igartua M, Hernández RM, Rosas JE, Patarroyo ME, Pedraz JL. Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides. Drug Deliv 2010; 17:490 - 9; http://dx.doi.org/10.3109/10717544.2010.483254; PMID: 20500129
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557 - 69; http://dx.doi.org/10.1038/nri3254; PMID: 22790179
   PubMed Web of Science ®Google Scholar
• McGuinness DH, Dehal PK, Pleass RJ. Pattern recognition molecules and innate immunity to parasites. Trends Parasitol 2003; 19:312 - 9; http://dx.doi.org/10.1016/S1471-4922(03)00123-5; PMID: 12855382
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003; 171:4984 - 9; PMID: 14607893
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505 - 17; http://dx.doi.org/10.1038/nrmicro1681; PMID: 17558426
   PubMed Web of Science ®Google Scholar
• Cox JC, Coulter AR. Adjuvants--a classification and review of their modes of action. Vaccine 1997; 15:248 - 56; http://dx.doi.org/10.1016/S0264-410X(96)00183-1; PMID: 9139482
   PubMed Web of Science ®Google Scholar
• Foti M, Granucci F, Ricciardi-Castagnoli P. A central role for tissue-resident dendritic cells in innate responses. Trends Immunol 2004; 25:650 - 4; http://dx.doi.org/10.1016/j.it.2004.10.007; PMID: 15530834
   PubMed Web of Science ®Google Scholar
• Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O’Hagan DT, Pétrilli V, Tschopp J, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009; 106:870 - 5; http://dx.doi.org/10.1073/pnas.0804897106; PMID: 19139407
   PubMed Web of Science ®Google Scholar
• Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev 2009; 229:337 - 55; http://dx.doi.org/10.1111/j.1600-065X.2009.00773.x; PMID: 19426232
   PubMed Web of Science ®Google Scholar
• Batzloff MR, Pandey M, Olive C, Good MF. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res 2006; 35:233 - 48; http://dx.doi.org/10.1385/IR:35:3:233; PMID: 17172649
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Kamaruzaman KA, Srinivasan S, Zaman M, Lin IC, Batzloff MR, Good MF, Toth I. M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus. Curr Drug Deliv 2013; 10:39 - 45; http://dx.doi.org/10.2174/1567201811310010007; PMID: 22998043
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Zaman M, Urbani CN, Lin IC, Jia Z, Batzloff MR, Good MF, Monteiro MJ, Toth I. Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew Chem Int Ed Engl 2010; 49:5742 - 5; http://dx.doi.org/10.1002/anie.201002221; PMID: 20818757
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Dougall AM, Khoshnejad M, Chandrudu S, Pearson MS, Loukas A, Toth I. Peptide-based subunit vaccine against hookworm infection. PLoS One 2012; 7:e46870; http://dx.doi.org/10.1371/journal.pone.0046870; PMID: 23056500
   PubMedGoogle Scholar
• Hickman HD, Luis AD, Buchli R, Few SR, Sathiamurthy M, VanGundy RS, Giberson CF, Hildebrand WH. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 2004; 172:2944 - 52; PMID: 14978097
   PubMed Web of Science ®Google Scholar
• Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 2000; 164:1625 - 33; PMID: 10640784
   PubMed Web of Science ®Google Scholar
• Glenny AT. Insoluble Precipitates in Diphtheria and Tetanus Immunization. Br Med J 1930; 2:244 - 5; http://dx.doi.org/10.1136/bmj.2.3632.244; PMID: 20775638
   PubMedGoogle Scholar
• Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007; 25:825 - 33; http://dx.doi.org/10.1016/j.vaccine.2006.09.039; PMID: 17014935
   PubMed Web of Science ®Google Scholar
• Morefield GL, HogenEsch H, Robinson JP, Hem SL. Distribution of adsorbed antigen in mono-valent and combination vaccines. Vaccine 2004; 22:1973 - 84; http://dx.doi.org/10.1016/j.vaccine.2003.10.040; PMID: 15121310
   PubMed Web of Science ®Google Scholar
• Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005; 23:1588 - 95; http://dx.doi.org/10.1016/j.vaccine.2004.07.050; PMID: 15694511
   PubMed Web of Science ®Google Scholar
• Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007; 6:685 - 98; http://dx.doi.org/10.1586/14760584.6.5.685; PMID: 17931150
   PubMed Web of Science ®Google Scholar
• Kool M, Soullié T, van Nimwegen M, Willart MAM, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205:869 - 82; http://dx.doi.org/10.1084/jem.20071087; PMID: 18362170
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Badenoch-Jones P, Turk JL. Complement activation by aluminium and zirconium compounds. Immunology 1979; 37:881 - 8; PMID: 500133
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008; 26:552 - 61; http://dx.doi.org/10.1016/j.vaccine.2007.11.054; PMID: 18162266
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122 - 6; http://dx.doi.org/10.1038/nature06939; PMID: 18496530
   PubMed Web of Science ®Google Scholar
• Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008; 38:2085 - 9; http://dx.doi.org/10.1002/eji.200838549; PMID: 18624356
   PubMed Web of Science ®Google Scholar
• Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011; 17:996 - 1002; http://dx.doi.org/10.1038/nm.2403; PMID: 21765404
   PubMed Web of Science ®Google Scholar
• Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 1968; 100:1139 - 40; PMID: 5648476
   PubMed Web of Science ®Google Scholar
• Cvjetanovic B, Uemura K. The Present Status of Field and Laboratory Studies of Typhoid and Paratyphoid Vaccines with Special Reference to Studies Sponsored by World Health Organization. Bull World Health Organ 1965; 32:29 - 36; PMID: 14290077
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium adjuvants--in retrospect and prospect. Vaccine 2004; 22:3658 - 68; http://dx.doi.org/10.1016/j.vaccine.2004.03.032; PMID: 15315845
   PubMed Web of Science ®Google Scholar
• Lew AM, Anders RF, Edwards SJ, Langford CJ. Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology 1988; 65:311 - 4; PMID: 3056855
   PubMed Web of Science ®Google Scholar
• Geerligs HJ, Weijer WJ, Welling GW, Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J Immunol Methods 1989; 124:95 - 102; http://dx.doi.org/10.1016/0022-1759(89)90190-7; PMID: 2553820
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19:2666 - 72; http://dx.doi.org/10.1016/S0264-410X(00)00498-9; PMID: 11257407
   PubMed Web of Science ®Google Scholar
• Tindle RW, Fernando GJP, Sterling JC, Frazer IH. A “public” T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci U S A 1991; 88:5887 - 91; http://dx.doi.org/10.1073/pnas.88.13.5887; PMID: 1712110
   PubMed Web of Science ®Google Scholar
• Oscherwitz J, Hankenson FC, Yu F, Cease KB. Low-dose intraperitoneal Freund’s adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide. Vaccine 2006; 24:3018 - 25; http://dx.doi.org/10.1016/j.vaccine.2005.10.046; PMID: 16307832
   PubMed Web of Science ®Google Scholar
• Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, et al, AIDS Vaccine Evaluation Group. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010; 5:e11995; http://dx.doi.org/10.1371/journal.pone.0011995; PMID: 20706632
   PubMed Web of Science ®Google Scholar
• Langermans JAM, Schmidt A, Vervenne RAW, Birkett AJ, Calvo-Calle JM, Hensmann M, Thornton GB, Dubovsky F, Weiler H, Nardin E, et al. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. Vaccine 2005; 23:4935 - 43; http://dx.doi.org/10.1016/j.vaccine.2005.05.036; PMID: 15998554
   PubMed Web of Science ®Google Scholar
• Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73:8017 - 26; http://dx.doi.org/10.1128/IAI.73.12.8017-8026.2005; PMID: 16299295
   PubMed Web of Science ®Google Scholar
• Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci 2010; 101:2110 - 4; http://dx.doi.org/10.1111/j.1349-7006.2010.01653.x; PMID: 20678155
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699 - 710; http://dx.doi.org/10.1586/14760584.6.5.699; PMID: 17931151
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995; 6:277 - 96; http://dx.doi.org/10.1007/978-1-4615-1823-5_10; PMID: 7551221
   PubMedGoogle Scholar
• O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012; 30:4341 - 8; http://dx.doi.org/10.1016/j.vaccine.2011.09.061; PMID: 22682289
   PubMed Web of Science ®Google Scholar
• Hu JJ, Wang HQ, Qu HG, Xu J, Yao ZB. [Antibody production and its neutralization of Abeta42's cytoxicity in BALB/c mice induced by Abeta42 and its subunit vaccines]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 2004; 20:178-81.
   Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740 - 5; http://dx.doi.org/10.1016/j.vaccine.2009.12.014; PMID: 20034605
   PubMed Web of Science ®Google Scholar
• Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012; 11:349 - 66; http://dx.doi.org/10.1586/erv.11.192; PMID: 22380826
   PubMed Web of Science ®Google Scholar
• De la Fuente M, Hernanz A, Guayerbas N, Victor VM, Arnalich F. Vitamin E ingestion improves several immune functions in elderly men and women. Free Radic Res 2008; 42:272 - 80; http://dx.doi.org/10.1080/10715760801898838; PMID: 18344122
   PubMed Web of Science ®Google Scholar
• Cheung YK, Cheng SCS, Ke Y, Xie Y. Two novel HLA-A*0201 T-cell epitopes in avian H5N1 viral nucleoprotein induced specific immune responses in HHD mice. Vet Res 2010; 41:24; http://dx.doi.org/10.1051/vetres/2009071; PMID: 19941812
   PubMed Web of Science ®Google Scholar
• Swinkels WJC, Hoeboer J, Sikkema R, Vervelde L, Koets AD. Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells. Virol J 2013; 10:206; http://dx.doi.org/10.1186/1743-422X-10-206; PMID: 23800100
   PubMed Web of Science ®Google Scholar
• Almanzar G, Herndler-Brandstetter D, Chaparro SV, Jenewein B, Keller M, Grubeck-Loebenstein B. Immunodominant peptides from conserved influenza proteins--a tool for more efficient vaccination in the elderly?. Wien Med Wochenschr 2007; 157:116 - 21; http://dx.doi.org/10.1007/s10354-007-0393-y; PMID: 17427008
   PubMedGoogle Scholar
• Cui C, Stevens VC, Schwendeman SP. Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine 2007; 25:500 - 9; http://dx.doi.org/10.1016/j.vaccine.2006.07.055; PMID: 16996662
   PubMed Web of Science ®Google Scholar
• Lutsiak MEC, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002; 19:1480 - 7; http://dx.doi.org/10.1023/A:1020452531828; PMID: 12425465
   PubMed Web of Science ®Google Scholar
• Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse C, Grotjahn D, Ichim T, et al. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine 2012; 7:1475 - 87; http://dx.doi.org/10.2147/IJN.S29506; PMID: 22619507
   PubMed Web of Science ®Google Scholar
• Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19:3033 - 42; http://dx.doi.org/10.1016/S0264-410X(01)00051-2; PMID: 11311997
   PubMed Web of Science ®Google Scholar
• Sáenz L, Neira-Carrillo A, Paredes R, Cortés M, Bucarey S, Arias JL. Chitosan formulations improve the immunogenicity of a GnRH-I peptide-based vaccine. Int J Pharm 2009; 369:64 - 71; http://dx.doi.org/10.1016/j.ijpharm.2008.10.033; PMID: 19041932
   PubMed Web of Science ®Google Scholar
• Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS, Cho CS. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 2008; 29:1931 - 9; http://dx.doi.org/10.1016/j.biomaterials.2007.12.025; PMID: 18221992
   PubMed Web of Science ®Google Scholar
• Li X, Min M, Du N, Gu Y, Hode T, Naylor M, Chen D, Nordquist RE, Chen WR. Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol 2013; 2013:387023; http://dx.doi.org/10.1155/2013/387023; PMID: 23533454
   PubMed Web of Science ®Google Scholar
• Boas U, Heegaard PMH. Dendrimers in drug research. Chem Soc Rev 2004; 33:43 - 63; http://dx.doi.org/10.1039/b309043b; PMID: 14737508
   PubMed Web of Science ®Google Scholar
• Ahmad Fuaad AA, Jia Z, Hartas J, Ziora ZM, Lin I, Moyle PM, Batzloff MR, Good MF, Monteiro MJ, Istvan T. Polymer–peptide hybrids as a highly immunogenic single-dose nanovaccine. nanomedicine (Lond) 2013.
   Google Scholar
• Zaman M, Skwarczynski M, Malcolm JM, Urbani CN, Jia Z, Batzloff MR, Good MF, Monteiro MJ, Toth I. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. Nanomedicine 2011; 7:168 - 73; PMID: 21034860
   PubMed Web of Science ®Google Scholar
• Liu TY, Hussein WM, Jia Z, Ziora ZM, McMillan NAJ, Monteiro MJ, Toth I, Skwarczynski M. Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules 2013; 14:2798 - 806; http://dx.doi.org/10.1021/bm400626w; PMID: 23837675
   PubMed Web of Science ®Google Scholar
• Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007; 28:5344 - 57; http://dx.doi.org/10.1016/j.biomaterials.2007.08.015; PMID: 17825905
   PubMed Web of Science ®Google Scholar
• Chong CSW, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 2005; 102:85 - 99; http://dx.doi.org/10.1016/j.jconrel.2004.09.014; PMID: 15653136
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O’Hagan DT. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 2006; 110:566 - 73; http://dx.doi.org/10.1016/j.jconrel.2005.10.010; PMID: 16360956
   PubMed Web of Science ®Google Scholar
• Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (Lond) 2012; 7:1877 - 93; http://dx.doi.org/10.2217/nnm.12.157; PMID: 23249332
   PubMed Web of Science ®Google Scholar
• Lincopan N, Espíndola NM, Vaz AJ, da Costa MHB, Faquim-Mauro E, Carmona-Ribeiro AM. Novel immunoadjuvants based on cationic lipid: Preparation, characterization and activity in vivo. Vaccine 2009; 27:5760 - 71; http://dx.doi.org/10.1016/j.vaccine.2009.07.066; PMID: 19664738
   PubMed Web of Science ®Google Scholar
• Schwendener RA, Ludewig B, Cerny A, Engler O. Liposome-Based Vaccines. Liposomes: Methods and Protocols, Vol 1 2010; 605:163-75.
   Google Scholar
• Ohno S, Kohyama S, Taneichi M, Moriya O, Hayashi H, Oda H, Mori M, Kobayashi A, Akatsuka T, Uchida T, et al. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice. Vaccine 2009; 27:3912 - 20; http://dx.doi.org/10.1016/j.vaccine.2009.04.001; PMID: 19490987
   PubMed Web of Science ®Google Scholar
• Espuelas S, Roth A, Thumann C, Frisch B, Schuber F. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells (vol 42, pg 721, 2005). Mol Immunol 2006; 43:772; http://dx.doi.org/10.1016/j.molimm.2005.04.003
   Web of Science ®Google Scholar
• Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, Geisler C, Andersen P. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121:216 - 26; http://dx.doi.org/10.1111/j.1365-2567.2007.02560.x; PMID: 17302734
   PubMed Web of Science ®Google Scholar
• Brgles M, Habjanec L, Halassy B, Tomasić J. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine 2009; 27:5435 - 42; http://dx.doi.org/10.1016/j.vaccine.2009.07.012; PMID: 19632317
   PubMed Web of Science ®Google Scholar
• Mann JFS, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 2009; 27:3643 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.03.040; PMID: 19464545
   PubMed Web of Science ®Google Scholar
• Korsholm KS, Petersen RV, Agger EM, Andersen P. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 2010; 129:75 - 86; http://dx.doi.org/10.1111/j.1365-2567.2009.03164.x; PMID: 19824919
   PubMed Web of Science ®Google Scholar
• Andersen CS, Agger EM, Rosenkrands I, Gomes JM, Bhowruth V, Gibson KJC, Petersen RV, Minnikin DE, Besra GS, Andersen P. A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J Immunol 2009; 182:424 - 32; PMID: 19109174
   PubMed Web of Science ®Google Scholar
• Tanaka T, Legat A, Adam E, Steuve J, Gatot JS, Vandenbranden M, Ulianov L, Lonez C, Ruysschaert JM, Muraille E, et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur J Immunol 2008; 38:1351 - 7; http://dx.doi.org/10.1002/eji.200737998; PMID: 18389479
   PubMed Web of Science ®Google Scholar
• Thomann JS, Heurtault B, Weidner S, Brayé M, Beyrath J, Fournel S, Schuber F, Frisch B. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 2011; 32:4574 - 83; http://dx.doi.org/10.1016/j.biomaterials.2011.03.015; PMID: 21474175
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145 - 60; http://dx.doi.org/10.1038/nrd1632; PMID: 15688077
   PubMed Web of Science ®Google Scholar
• Ruedl C, Storni T, Lechner F, Bächi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002; 32:818 - 25; http://dx.doi.org/10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U; PMID: 11870626
   PubMed Web of Science ®Google Scholar
• Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998; 28:1401 - 7; http://dx.doi.org/10.1002/(SICI)1521-4141(199804)28:04<1401::AID-IMMU1401>3.0.CO;2-M; PMID: 9565380
   PubMed Web of Science ®Google Scholar
• Guillen G, Aguilar JC, Duenas S, Hermida L, Guzman MG, Penton E, Iglesias E, Junco J, Torrens I, Lobaina Y, et al. Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. Procedia Vaccinol 2010; 2:128 - 33; http://dx.doi.org/10.1016/j.provac.2010.07.004
   Google Scholar
• Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother 2010; 59:1685 - 96; http://dx.doi.org/10.1007/s00262-010-0895-0; PMID: 20652244
   PubMed Web of Science ®Google Scholar
• FDA Licensure of Bivalent Human Papillomavirus Vaccine. (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations From the Advisory Committee on Immunization Practices (ACIP) (Reprinted from MMWR, vol 59, pg 626-629, 2010). Jama-J Am Med Assoc 2010; 304:632 - 4
   Web of Science ®Google Scholar
• Liu TY, Hussein WM, Toth I, Skwarczynski M. Advances in peptide-based human papillomavirus therapeutic vaccines. Curr Top Med Chem 2012; 12:1581 - 92; http://dx.doi.org/10.2174/156802612802652402; PMID: 22827526
   PubMed Web of Science ®Google Scholar
• Homhuan A, Prakongpan S, Poomvises P, Maas RA, Crommelin DJA, Kersten GFA, Jiskoot W. Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity. Eur J Pharm Sci 2004; 22:459 - 68; http://dx.doi.org/10.1016/j.ejps.2004.05.005; PMID: 15265516
   PubMed Web of Science ®Google Scholar
• Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15:518 - 29; http://dx.doi.org/10.1016/j.copbio.2004.10.005; PMID: 15560978
   PubMed Web of Science ®Google Scholar
• Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005; 23:1232 - 41; http://dx.doi.org/10.1016/j.vaccine.2004.09.002; PMID: 15652665
   PubMed Web of Science ®Google Scholar
• Angel J, Chaperot L, Molens JP, Mezin P, Amacker M, Zurbriggen R, Grichine A, Plumas J. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 2007; 25:3913 - 21; http://dx.doi.org/10.1016/j.vaccine.2007.01.101; PMID: 17336432
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Hengartner H, Zinkernagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?. Eur J Immunol 1995; 25:3445 - 51; http://dx.doi.org/10.1002/eji.1830251236; PMID: 8566036
   PubMed Web of Science ®Google Scholar
• Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, Sauerwein RW, Robinson JA, Genton B, Mazier D, et al. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One 2007; 2:e1278; http://dx.doi.org/10.1371/journal.pone.0001278; PMID: 18060072
   PubMed Web of Science ®Google Scholar
• Hunziker IP, Zurbriggen R, Glueck R, Engler OB, Reichen J, Dai WJ, Pichler WJ, Cerny A. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 2001; 38:475 - 84; http://dx.doi.org/10.1016/S0161-5890(01)00083-9; PMID: 11741697
   PubMed Web of Science ®Google Scholar
• Cho JE, Kim HS, Ahn WS, Park YS. Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins. J Microencapsul 2001; 18:421 - 31; http://dx.doi.org/10.1080/02652040010019550; PMID: 11428672
   PubMed Web of Science ®Google Scholar
• Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One 2007; 2:e1018; http://dx.doi.org/10.1371/journal.pone.0001018; PMID: 17925866
   PubMed Web of Science ®Google Scholar
• Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011; 187:55 - 63; http://dx.doi.org/10.4049/jimmunol.1004114; PMID: 21613613
   PubMed Web of Science ®Google Scholar
• Furrie E, Smith RE, Turner MW, Strobel S, Mowat AM. Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine 2002; 20:2254 - 62; http://dx.doi.org/10.1016/S0264-410X(02)00106-8; PMID: 12009281
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101:10697 - 702; http://dx.doi.org/10.1073/pnas.0403572101; PMID: 15252201
   PubMed Web of Science ®Google Scholar
• Kensil CR, Wu JY, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 1995; 6:525 - 41; http://dx.doi.org/10.1007/978-1-4615-1823-5_22; PMID: 7551234
   PubMedGoogle Scholar
• Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine 2002; 20:2808 - 15; http://dx.doi.org/10.1016/S0264-410X(02)00209-8; PMID: 12034108
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 2003; 8:934 - 43; http://dx.doi.org/10.1016/S1359-6446(03)02864-2; PMID: 14554157
   PubMed Web of Science ®Google Scholar
• Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000; 151:673 - 84; http://dx.doi.org/10.1083/jcb.151.3.673; PMID: 11062267
   PubMed Web of Science ®Google Scholar
• Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE, Farmer JT, Koratich MS, May RD. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 2000; 18:3141 - 51; http://dx.doi.org/10.1016/S0264-410X(00)00118-3; PMID: 10856794
   PubMed Web of Science ®Google Scholar
• Marciani DJ, Pathak AK, Reynolds RC, Seitz L, May RD. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int Immunopharmacol 2001; 1:813 - 8; http://dx.doi.org/10.1016/S1567-5769(01)00016-9; PMID: 11357894
   PubMed Web of Science ®Google Scholar
• Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000; 19:530 - 7; http://dx.doi.org/10.1016/S0264-410X(00)00195-X; PMID: 11027818
   PubMed Web of Science ®Google Scholar
• Jung JP, Nagaraj AK, Fox EK, Rudra JS, Devgun JM, Collier JH. Co-assembling peptides as defined matrices for endothelial cells. Biomaterials 2009; 30:2400 - 10; http://dx.doi.org/10.1016/j.biomaterials.2009.01.033; PMID: 19203790
   PubMed Web of Science ®Google Scholar
• Malashkevich VN, Kammerer RA, Efimov VP, Schulthess T, Engel J. The crystal structure of a five-stranded coiled coil in COMP: a prototype ion channel?. Science 1996; 274:761 - 5; http://dx.doi.org/10.1126/science.274.5288.761; PMID: 8864111
   PubMed Web of Science ®Google Scholar
• Burkhard P, Meier M, Lustig A. Design of a minimal protein oligomerization domain by a structural approach. Protein Sci 2000; 9:2294 - 301; http://dx.doi.org/10.1110/ps.9.12.2294; PMID: 11206050
   PubMed Web of Science ®Google Scholar
• Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol 2009; 183:7268 - 77; http://dx.doi.org/10.4049/jimmunol.0901957; PMID: 19915055
   PubMed Web of Science ®Google Scholar
• Pimentel T, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P. Peptide nanoparticles as novel immunogens: Design and biophysical analysis of a prototype SARS vaccine. Abstr Pap Am Chem S 2009; 237:443
   Web of Science ®Google Scholar
• Rudra JS, Tian YF, Jung JP, Collier JH. A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A 2010; 107:622 - 7; http://dx.doi.org/10.1073/pnas.0912124107; PMID: 20080728
   PubMed Web of Science ®Google Scholar
• Rudra JS, Mishra S, Chong AS, Mitchell RA, Nardin EH, Nussenzweig V, Collier JH. Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials 2012; 33:6476 - 84; http://dx.doi.org/10.1016/j.biomaterials.2012.05.041; PMID: 22695068
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Kowapradit J, Ziora ZM, Toth I. pH-triggered peptide self-assembly into fibrils: a potential peptide-based subunit vaccine delivery platform. Bio Chem Comp 2013; 1.
   Google Scholar
• Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999; 19:103 - 7; http://dx.doi.org/10.1006/meth.1999.0834; PMID: 10525445
   PubMed Web of Science ®Google Scholar
• Ismaili J, Rennesson J, Aksoy E, Vekemans J, Vincart B, Amraoui Z, Van Laethem F, Goldman M, Dubois PM. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002; 168:926 - 32; PMID: 11777991
   PubMed Web of Science ®Google Scholar
• Jiang ZH, Budzynski WA, Qiu D, Yalamati D, Koganty RR. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity. Carbohydr Res 2007; 342:784 - 96; http://dx.doi.org/10.1016/j.carres.2007.01.012; PMID: 17300769
   PubMed Web of Science ®Google Scholar
• Blunck R, Scheel O, Müller M, Brandenburg K, Seitzer U, Seydel U. New insights into endotoxin-induced activation of macrophages: involvement of a K+ channel in transmembrane signaling. J Immunol 2001; 166:1009 - 15; PMID: 11145680
   PubMed Web of Science ®Google Scholar
• Sigalov AB. “Monovalent” ligands that trigger TLR-4 and TCR are not necessarily truly monovalent. Mol Immunol 2012; 51:356 - 62; http://dx.doi.org/10.1016/j.molimm.2012.03.031; PMID: 22520974
   PubMed Web of Science ®Google Scholar
• Seydel U, Hawkins L, Schromm AB, Heine H, Scheel O, Koch MHJ, Brandenburg K. The generalized endotoxic principle. Eur J Immunol 2003; 33:1586 - 92; http://dx.doi.org/10.1002/eji.200323649; PMID: 12778476
   PubMed Web of Science ®Google Scholar
• Fujita Y, Taguchi H. Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles. Chem Cent J 2011; 5:48; http://dx.doi.org/10.1186/1752-153X-5-48; PMID: 21861904
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem 2008; 15:506 - 16; http://dx.doi.org/10.2174/092986708783503249; PMID: 18289006
   PubMed Web of Science ®Google Scholar
• Tabatabai LB, Pugh GW Jr.. Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine 1994; 12:919 - 24; http://dx.doi.org/10.1016/0264-410X(94)90035-3; PMID: 7526568
   PubMed Web of Science ®Google Scholar
• Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005; 23:4148 - 57; http://dx.doi.org/10.1016/j.vaccine.2005.03.019; PMID: 15964483
   PubMed Web of Science ®Google Scholar
• Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect 2005; 7:922 - 31; http://dx.doi.org/10.1016/j.micinf.2005.03.011; PMID: 15935717
   PubMed Web of Science ®Google Scholar
• Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009; 27:2099 - 107; http://dx.doi.org/10.1016/j.vaccine.2009.02.011; PMID: 19356612
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Hong SH, Ung TT, Verma V, Kim SY, Rhee JH, Lee SE. Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. Clin Exp Vaccine Res 2013; 2:128 - 34; http://dx.doi.org/10.7774/cevr.2013.2.2.128; PMID: 23858404
   PubMedGoogle Scholar
• Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61:195 - 204; http://dx.doi.org/10.1016/j.addr.2008.12.008; PMID: 19211030
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Pircher H, Lipford GB, Häcker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 2000; 164:2372 - 8; PMID: 10679072
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011; 10:499 - 511; http://dx.doi.org/10.1586/erv.10.174; PMID: 21506647
   PubMed Web of Science ®Google Scholar
• Daftarian P, Sharan R, Haq W, Ali S, Longmate J, Termini J, Diamond DJ. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 2005; 23:3453 - 68; http://dx.doi.org/10.1016/j.vaccine.2005.01.093; PMID: 15837369
   PubMed Web of Science ®Google Scholar
• Meshcheryakova E, Makarov E, Philpott D, Andronova T, Ivanov V. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine 2007; 25:4515 - 20; http://dx.doi.org/10.1016/j.vaccine.2007.04.006; PMID: 17481783
   PubMed Web of Science ®Google Scholar
• Moreira LO, Smith AM, DeFreitas AA, Qualls JE, El Kasmi KC, Murray PJ. Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 2008; 26:5808 - 13; http://dx.doi.org/10.1016/j.vaccine.2008.08.038; PMID: 18789992
   PubMed Web of Science ®Google Scholar
• Zaman M, Skwarczynski M, Toth I. Toll-Like Receptor 2 Mediated Dendritic Cell Activation-Key Target for Lipopeptide Vaccines Design. Cell Bio Res Prog 2010:63-80.
   Google Scholar
• Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808 - 12; http://dx.doi.org/10.1038/nature04596; PMID: 16489357
   PubMed Web of Science ®Google Scholar
• Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169:4905 - 12; PMID: 12391202
   PubMed Web of Science ®Google Scholar
• Deres K, Schild H, Wiesmüller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989; 342:561 - 4; http://dx.doi.org/10.1038/342561a0; PMID: 2586628
   PubMed Web of Science ®Google Scholar
• Eriksson EMY, Jackson DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 2007; 8:412 - 7; http://dx.doi.org/10.2174/138920307781369436; PMID: 17696872
   PubMed Web of Science ®Google Scholar
• Chua BY, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J, Jackson DC. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008; 26:4866 - 75; http://dx.doi.org/10.1016/j.vaccine.2008.03.032; PMID: 18455278
   PubMed Web of Science ®Google Scholar
• Kamo K, Jordan R, Hsu H, Hudson D. Development of a monoclonal antibody to the conserved region of p34cdc2 protein kinase. J Immunol Methods 1992; 156:163 - 70; http://dx.doi.org/10.1016/0022-1759(92)90022-L; PMID: 1474253
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Zaman M, Toth I. Lipo-peptides/saccharides in peptide vaccine delivery. In handbook of the biologically active peptides 2013:571-9.
   Google Scholar
• Zaman M, Abdel-Aal AB, Phillipps KSM, Fujita Y, Good MF, Toth I. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine 2010; 28:2243 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.12.046; PMID: 20045502
   PubMed Web of Science ®Google Scholar
• Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005; 23:2298 - 303; http://dx.doi.org/10.1016/j.vaccine.2005.01.041; PMID: 15755615
   PubMed Web of Science ®Google Scholar
• Zhong W, Skwarczynski M, Toth I. Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Aust J Chem 2009; 62:956 - 67; http://dx.doi.org/10.1071/CH09149
   Web of Science ®Google Scholar
• Moyle PM, Olive C, Ho M-F, Pandey M, Dyer J, Suhrbier A, Fujita Y, Toth I. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem 2007; 50:4721 - 7; http://dx.doi.org/10.1021/jm070287b; PMID: 17705361
   PubMed Web of Science ®Google Scholar
• Apte SH, Groves PL, Skwarczynski M, Fujita Y, Chang C, Toth I, Doolan DL. Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model. PloS one 2012; 7:e40928-e.
   Google Scholar
• Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 2006; 18:1801 - 13; http://dx.doi.org/10.1093/intimm/dxl114; PMID: 17077175
   PubMed Web of Science ®Google Scholar
• Kumar A, Arora R, Kaur P, Chauhan VS, Sharma P. “Universal” T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide. J Immunol 1992; 148:1499 - 505; PMID: 1371529
   PubMed Web of Science ®Google Scholar
• Zaman M, Abdel-Aal ABM, Fujita Y, Phillipps KSM, Batzloff MR, Good MF, Toth I. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One 2012; 7:e30146; http://dx.doi.org/10.1371/journal.pone.0030146; PMID: 22253911
   PubMedGoogle Scholar
• Brown LE, Jackson DC. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv 2005; 2:383 - 93; http://dx.doi.org/10.2174/156720105774370258; PMID: 16305441
   PubMedGoogle Scholar